Fetal RhD NIPT: A new testing option to inform care for RhD alloimmunized patients and those at risk

Natera’s™ Fetal RhD noninvasive prenatal testing (NIPT) is now available. The test is backed by the largest clinical validation study for fetal RhD in the US to date, and demonstrated 100% sensitivity, 99.3% specificity^[1].

Join our presentation to:

• Review RhD and its role in pregnancy.
• See our clinical validation study including 655 Rh negative pregnant people and confirmation by serology on all newborns
• Discuss how fetal RhD NIPT adds to current management of pregnant people who are Rh negative
• Ask questions during our live Q&A following the presentation

1.Meltzer et al., Validation of a SNP-based Prenatal cell-free DNA screening for Fetal RhD Status in a Large US Cohort, ACOG Annual Clinical and Scientific Meeting, May 2024, San Francisco, CA.

Jeffrey T. Meltzer, MD, MBA
Senior Medical Director, Natera


Vivenne Souter, MD, MPH
Medical Director, Natera